Areteus s.r.o.
- Address
- lock Available on a paid plan
Areteus s.r.o. - Cardiometabolic Research Center
Areteus s.r.o. is a clinical research facility specializing in cardiometabolic disorders and their complications. The center demonstrates significant expertise in conducting Phase III trials focused on metabolic disease management, with particular emphasis on diabetes, obesity, and kidney function preservation. Their research portfolio reflects a commitment to evaluating novel therapeutic approaches that address the interconnected nature of cardiovascular, metabolic, and renal health.
- Type 2 Diabetes Mellitus management and glycemic control strategies
- Chronic Kidney Disease progression and proteinuria reduction therapies
- Severe dyslipidemia including hypertriglyceridemia treatment
- Obesity management with focus on cardiovascular and renal outcomes
The center's research infrastructure supports comprehensive evaluation of both safety and efficacy endpoints in complex patient populations. Areteus s.r.o. plays a vital role in advancing therapeutic options for patients with multiple comorbidities, particularly those at risk for cardiovascular events and progressive kidney disease. Their participation in large-scale outcomes trials demonstrates capability in long-term patient follow-up and monitoring of clinically meaningful endpoints including cardiovascular outcomes and kidney function preservation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AstraZeneca AB1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB4trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Areteus s.r.o.
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia (SHTG) | Ionis Pharmaceuticals Inc. | Phase III | Not Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 4 | Unknown | 2023-08-02 | 2024-04-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.